Approximating Protein Flexibility through Dynamic Pharmacophore Models: Application to Fatty Acid Amide Hydrolase (FAAH)
暂无分享,去创建一个
[1] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[2] Daniele Piomelli,et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.
[3] Heather A Carlson,et al. Protein flexibility is an important component of structure-based drug discovery. , 2002, Current pharmaceutical design.
[4] Joseph Tam,et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. , 2010, Chemistry & biology.
[5] Hongfeng Deng,et al. Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors , 2010, Expert opinion on drug discovery.
[6] Raymond C Stevens,et al. X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. , 2010, Journal of medicinal chemistry.
[7] J A McCammon,et al. Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.
[8] Heather A. Carlson,et al. Incorporating Dynamics in E. coli Dihydrofolate Reductase Enhances Structure-Based Drug Discovery , 2007, J. Chem. Inf. Model..
[9] Stephen P. Mayfield,et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.
[10] Marya Liimatta,et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. , 2007, Biochemistry.
[11] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[12] Heather A Carlson,et al. Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.
[13] H. Carlson. Protein flexibility and drug design: how to hit a moving target. , 2002, Current opinion in chemical biology.
[14] Dale L Boger,et al. Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. , 2008, Journal of medicinal chemistry.
[15] B. Cravatt,et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[17] Zhihua Ma,et al. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH) , 2011, Proceedings of the National Academy of Sciences.
[18] T. Nevalainen,et al. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. , 2010, Current topics in medicinal chemistry.
[19] Raymond C Stevens,et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.
[20] Claudia Silva,et al. Structure–Property Relationships of a Class of Carbamate‐Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability , 2009, ChemMedChem.
[21] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[22] Richard A. Lewis,et al. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. , 2004, Journal of medicinal chemistry.
[23] David Butler,et al. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. , 2010, Life sciences.
[24] Raymond C Stevens,et al. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. , 2010, Journal of molecular biology.
[25] Giovanni Piersanti,et al. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. , 2008, Journal of medicinal chemistry.
[26] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[27] Giovanni Piersanti,et al. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.
[28] Katrina W Lexa,et al. Full protein flexibility is essential for proper hot-spot mapping. , 2011, Journal of the American Chemical Society.
[29] Gilles Marcou,et al. Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..
[30] Henri Xhaard,et al. Screening of Various Hormone‐Sensitive Lipase Inhibitors as Endocannabinoid‐Hydrolyzing Enzyme Inhibitors , 2009, ChemMedChem.
[31] Hongma Sun,et al. Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.
[32] S. Teague. Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.
[33] Alan Saghatelian,et al. Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[34] Raymond C Stevens,et al. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling , 2002, Science.
[35] Raymond C Stevens,et al. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. , 2009, Journal of the American Chemical Society.
[36] T. Cassano,et al. Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] Heather A Carlson,et al. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.
[38] Woody Sherman,et al. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..
[39] Gerard J Kleywegt,et al. Limitations and lessons in the use of X-ray structural information in drug design , 2008, Drug Discovery Today.
[40] Rommie E. Amaro,et al. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design , 2008, J. Comput. Aided Mol. Des..
[41] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[42] Raymond C Stevens,et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion , 2008, Proceedings of the National Academy of Sciences.
[43] Woody Sherman,et al. Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis , 2009, J. Chem. Inf. Model..
[44] Benjamin F. Cravatt,et al. Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase , 2007 .
[45] Holger Gohlke,et al. Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.